11.30
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
What analysts say about Theravance Biopharma Inc. stockExplosive trading growth - jammulinksnews.com
Theravance Biopharma Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Exclusive: Theravance Biopharma Leadership Reveals Strategic Updates at BTIG Conference Next Week - Stock Titan
Is Theravance Biopharma Inc. a good long term investmentFast-track wealth growth - jammulinksnews.com
What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Theravance Biopharma Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World
Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener
Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener
Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com
Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World
Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus
(TBPH) Proactive Strategies - news.stocktradersdaily.com
Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):